Regeneron Pharmaceuticals Performance

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

On a scale of 0 to 100 Regeneron Pharmaceuticals holds performance score of 9. The organization holds Beta of 0.8811 which implies Regeneron Pharmaceuticals returns are very sensitive to returns on the market. as market goes up or down, Regeneron Pharmaceuticals is expected to follow. Although it is vital to follow to Regeneron Pharmaceuticals current trending patterns, it is good to be conservative about what you can actually do with the information regarding equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing Regeneron Pharmaceuticals technical indicators you can presently evaluate if the expected return of 0.2629% will be sustainable into the future. Please employ Regeneron Pharmaceuticals Downside Variance, and the relationship between Sortino Ratio and Accumulation Distribution to make a quick decision on weather Regeneron Pharmaceuticals historical price patterns will revert.

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Regeneron Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 30 days. Allthough quite weak forward indicators, Regeneron Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Quick Ratio3.16
Fifty Two Week Low271.37
Target High Price510.00
Fifty Two Week High442.00
Target Low Price324.00
Horizon     30 Days    Login   to change

Regeneron Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  30,621  in Regeneron Pharmaceuticals on December 24, 2019 and sell it today you would earn a total of  5,039  from holding Regeneron Pharmaceuticals or generate 16.46% return on investment over 30 days. Regeneron Pharmaceuticals is currently generating 0.2629% of daily expected returns and assumes 1.8563% risk (volatility on return distribution) over the 30 days horizon. In different words, 16% of equities are less volatile than Regeneron Pharmaceuticals and 96% of traded equity instruments are projected to make higher returns than the company over the 30 days investment horizon.
 Daily Expected Return (%) 
  Risk (%) 
Given the investment horizon of 30 days, Regeneron Pharmaceuticals is expected to generate 3.89 times more return on investment than the market. However, the company is 3.89 times more volatile than its market benchmark. It trades about 0.14 of its potential returns per unit of risk. The DOW is currently generating roughly 0.27 per unit of risk.

Regeneron Pharmaceuticals Market Risk Analysis

Sharpe Ratio = 0.1416
Good Returns
Average Returns
Small ReturnsREGN
Negative Returns

Regeneron Pharmaceuticals Relative Performance Indicators

Estimated Market Risk
  actual daily
 16 %
of total potential
Expected Return
  actual daily
 4 %
of total potential
Risk-Adjusted Return
  actual daily
 9 %
of total potential
Based on monthly moving average Regeneron Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regeneron Pharmaceuticals by adding it to a well-diversified portfolio.

Regeneron Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions

About 74.0% of the company shares are owned by institutional investors
Latest headline from A Look At Some Cash Alternatives For your Portfolios Regeneron Pharmaceuticals, Inc., - NewsSmooth
Additionally take a look at Your Equity Center. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.
Company logos by clearbit